ANGO
AngioDynamics, Inc.
ANGO offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
UNH
UnitedHealth Group Incorporated
UNH has the edge over ANGO overall, supported by stronger modeled upside and lower modeled downside.
ANGO Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Stable | |
| Strong |
ANGO's balance sheet is currently strong, and its revenue and cash flow are stable, but its profitability is under pressure.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
ANGO PE Valuation
ANGO has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
ANGO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Improving | |
| Limited | |
| High |
ANGO has the edge over UNH on the outlook, with more favorable revenue expectations.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
ANGO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.79 | -$0.01 |
| Q2 2026 | -$0.88 | -$0.05 |
| Q1 2026 | -$0.75 | +$0.28 |
| Q4 2025 | -$0.67 | +$4.92 |
| Q3 2025 | -$0.78 | +$5.27 |
| Q2 2025 | -$0.83 | +$3.76 |
| Q1 2025 | -$1.03 | +$3.76 |
| Q4 2024 | -$5.59 | -$5.23 |
ANGO is still losing money, but far less than before: $0.79 per share over the past year, against $6.05 at its worst in mid-2024.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over ANGO on earnings quality, reporting a profit while its opponent remains loss making.
ANGO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $80.9M | +6.9% |
| Q2 2026 | $86.6M | +8% |
| Q1 2026 | $78.4M | +8.9% |
| Q4 2025 | $79.4M | +9% |
| Q3 2025 | $75.7M | +12% |
| Q2 2025 | $80.2M | +13% |
| Q1 2025 | $72M | -4.2% |
| Q4 2024 | $72.8M | -7.9% |
ANGO's revenue has grown year over year for six quarters in a row: $81M last quarter, up 6.9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -9% | +5.1 points |
| Q2 2026 | -12% | -4.5 points |
| Q1 2026 | -17% | -2.7 points |
| Q4 2025 | -7.7% | +7.5 points |
| Q3 2025 | -14% | +5.3 points |
| Q2 2025 | -7.2% | +13 points |
| Q1 2025 | -14% | +252 points |
| Q4 2024 | -15% | +1.4 points |
ANGO's operating margin was −9% last quarter, up 5.1 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over ANGO on profitability, with a higher operating margin.
ANGO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$15.7M | +$936K |
| Q2 2026 | $17M | -5.5% |
| Q1 2026 | -$4.1M | +$10.8M |
| Q4 2025 | $4.2M | +153% |
| Q3 2025 | -$16.6M | +$2.7M |
| Q2 2025 | $18M | +307% |
| Q1 2025 | -$15M | -$1.8M |
| Q4 2024 | $1.7M | -64% |
ANGO's free cash flow has turned positive after two years mostly in the red: $1M over the past year.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH still generates free cash flow, though less than at its 2022 peak: $22.8B over the past year.
ANGO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.2% | +496K shares |
| 1 year | +2.1% | +848K shares |
| 3 years | +5.1% | +2.1M shares |
| 5 years | +8.5% | +3.3M shares |
| Available history | +11% | +4M shares |
ANGO has 42M diluted shares, up 2.1% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $1.1M |
| Q3 2024 | $552,000 |
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over ANGO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
ANGO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2023 | -2.9x | Net Cash |
| Q3 2023 | -2.1x | Net Cash |
| Q2 2022 | -32.8x | Net Cash |
| Q4 2019 | -6.1x | Net Cash |
ANGO has more cash than debt.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
ANGO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.7 | Neutral |
| Stochastic | 22.6 | Neutral |
ANGO's weekly RSI is 43 (neutral) and its Stochastic is 23 (neutral).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
ANGO PE vs Healthcare Sector
| Metric | ANGO | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ANGO has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
ANGO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $12.7 | 5.5% below |
| 20 week MA | $13.9 | 14% below |
| 50 week MA | $12.4 | 3.4% below |
| 100 week MA | $11.3 | 5.7% above |
| 200 week MA | $9.60 | 25% above |
ANGO has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 25% above its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over ANGO on trend strength, trading above more of its moving averages.
ANGO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $16.0 | $14.1 | -11% |
| 2021 | $14.1 | $28.2 | +100% |
| 2022 | $28.2 | $13.3 | -53% |
| 2023 | $13.3 | $7.84 | -41% |
| 2024 | $7.84 | $8.91 | +14% |
| 2025 | $8.91 | $13.1 | +47% |
| 2026 YTD | $13.1 | $12.0 | -8.5% |
ANGO has finished lower in three of the last six years. It's down 8.5% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over ANGO on returns for 2026, with the stronger performance.